About this item
Few were ready when a mysterious respiratory illness emerged in Wuhan, China in January 2020. Politicians, government officials, business leaders, and public-health professionals were unprepared for the most devastating pandemic in a century. Many of the world's biggest drug and vaccine makers were slow to react or couldn't muster an effective response. It was up to a small group of unlikely and untested scientists and executives to save civilization. A French businessman dismissed by many as a fabulist. A Turkish immigrant with little virus experience. A quirky Midwesterner obsessed with insect cells. A Boston scientist employing questionable techniques. A British scientist despised by his peers. Far from the limelight, each had spent years developing innovative vaccine approaches.
About the Author
Gregory Zuckerman is a Special Writer at The Wall Street Journal. He writes about big financial trades, firms and personalities, among other investing and business topics, and regularly pens the widely read "Heard on the Street" column. He's a three-time winner of the Gerald Loeb award, the highest honor in business journalism. Greg won the Loeb Award in 2015 for a series of stories revealing discord between Bill Gross, founder of bond powerhouse Pimco, and others at the firm, stories that led to his departure. In 2012, Greg broke news about huge, disastrous trades by the J.P. Morgan trader nicknamed the "London Whale," trades that resulted in $6.2 billion losses for the bank.Greg appears regularly on CNBC, Fox Business and other networks and he makes appearances on radio stations around the globe. Greg joined the Journal in 1996 after writing about media companies for the New York Post. He graduated from Brandeis University in 1988. Greg lives with his wife and two sons in West Orange, N.J., where they enjoy the New York Yankees in the summer, root for the Giants in the fall, and reminisce about Linsanity in the winter.
